Statement on efforts to help make development of biosimilar and interchangeable insulin products more efficient
US Food and Drug Administration - FDA
US Food and Drug Administration
25 November 2019
This draft guidance is intended to help guide efficient product development by clarifying what data and information may, or may not be needed to support a demonstration of biosimilarity or interchangeability for a proposed insulin product.